Scinai Immunotherapeutics Ltd logo

Scinai Immunotherapeutics Ltd - ADR

FRA:2F5 (Israel)   ADR
€ 3.04 (-2.56%) Sep 12
At Loss
Market Cap:
€ 2.55M ($ 2.83M)
Enterprise V:
€ 18.66M ($ 20.69M)
Volume:
-
Avg Vol (2M):
1.26K
Trade In:

Business Description

Scinai Immunotherapeutics Ltd logo
Scinai Immunotherapeutics Ltd

ISIN : US09073Q1058

Share Class Description:

FRA:2F5: ADR
Description
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.15
Equity-to-Asset -0.49
Debt-to-Equity -2.86
Debt-to-EBITDA -2.98
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -11.6
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -110.7
3-Year FCF Growth Rate 51.2
3-Year Book Growth Rate 37
Name Current Vs Industry Vs History
5-Day RSI 37.49
9-Day RSI 38.98
14-Day RSI 42
6-1 Month Momentum % -27.56
12-1 Month Momentum % -71.9

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.19
Quick Ratio 2.19
Cash Ratio 1.84
Days Sales Outstanding 152.94

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -59.1
Shareholder Yield % 43.89
Name Current Vs Industry Vs History
Operating Margin % -2774.65
Net Margin % -1304.23
FCF Margin % -2434.09
ROA % -21.08
ROIC % -64.66
3-Year ROIIC % 57.17
ROC (Joel Greenblatt) % -66.76
ROCE % -49.84

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 7.66
EV-to-EBIT -2.6
EV-to-EBITDA -2.93
EV-to-Revenue 72.41
EV-to-FCF -2.97
Earnings Yield (Greenblatt) % -38.39
FCF Yield % -249.1

Financials

FRA:2F5's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Scinai Immunotherapeutics Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 0.264
EPS (TTM) (€) -7.236
Beta 2.54
Volatility % 77.43
14-Day RSI 42
14-Day ATR (€) 0.187226
20-Day SMA (€) 3.395
12-1 Month Momentum % -71.9
52-Week Range (€) 2.5 - 12.8
Shares Outstanding (Mil) 0.84

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Scinai Immunotherapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Scinai Immunotherapeutics Ltd Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Scinai Immunotherapeutics Ltd Frequently Asked Questions

What is Scinai Immunotherapeutics Ltd(FRA:2F5)'s stock price today?
The current price of FRA:2F5 is €3.04. The 52 week high of FRA:2F5 is €12.80 and 52 week low is €2.50.
When is next earnings date of Scinai Immunotherapeutics Ltd(FRA:2F5)?
The next earnings date of Scinai Immunotherapeutics Ltd(FRA:2F5) is .
Does Scinai Immunotherapeutics Ltd(FRA:2F5) pay dividends? If so, how much?
Scinai Immunotherapeutics Ltd(FRA:2F5) does not pay dividend.

Press Release

Subject Date
No Press Release